RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACISTS TEST-AND-TREAT, AUTHORITY ACT
Impact
If enacted, this bill would significantly alter provisions in existing Rhode Island law regarding healthcare delivery, effectively integrating pharmacists into the wider public health strategy. By allowing pharmacists to perform tests and provide necessary treatment based on established protocols, S2851 aims to ensure that patients receive timely care for conditions such as influenza, COVID-19, and streptococcal infections. Coverage for these services would be mandated in health insurance plans, ensuring that patients can afford such treatments without additional out-of-pocket costs, reinforcing the role of pharmacists in the healthcare continuum.
Summary
S2851, known as the Pharmacists Test-and-Treat Authority Act, seeks to empower licensed pharmacists to independently conduct tests and initiate treatment for certain common health conditions. This initiative is designed to enhance access to healthcare services by utilizing the accessibility of pharmacists, who are often available to patients without the need for an appointment, thereby helping to alleviate pressures on emergency and urgent care facilities. The tests covered under this Act would include CLIA-waived tests, which are straightforward laboratory tests that can be administered in a pharmacy setting.
Contention
However, the bill may face scrutiny and debate regarding the scope of pharmacists' new responsibilities, particularly concerning the safety and appropriateness of treatment protocols. Critics may express concerns about patients receiving care from non-physicians, especially for conditions that typically require a higher level of medical evaluation. Furthermore, the requirement for health insurers to cover these services may raise questions about the potential increase in insurance premiums or the bureaucratic implications of more providers being involved in patient care.
Additional_context
Ultimately, if successfully implemented, S2851 could redefine the role of pharmacists in Rhode Island, helping to meet a growing demand for accessible healthcare while striving to maintain standards of care and patient safety. The future deliberation over this Act is poised to reflect broader trends in efforts to expand healthcare access in the United States.
Restricts audits of pharmacists conducted by insurers and their intermediaries, limiting audits to one per year unless fraud or misrepresentation is reasonably suspected. The RI attorney general has the authority to impose sanctions for violations.
Expands the existing law regarding collaborative practice agreements between pharmacists and physicians to allow other healthcare providers to enter into such agreements and removes the definition of “collaborative practice committee.”
Authorizes a midwife, nurse practitioner or physicians assistant attending a newborn to cause that child to be subject to newborn screening tests for conditions for which there is a medical benefit to the early detection and treatment of the disorder.
Prohibits an insurer from imposing a requirement of prior authorization for any admission, item, service, treatment, test, exam, study, procedure, or any generic or brand name prescription drug ordered by a primary care provider.
Authorizes a midwife, nurse practitioner or physicians assistant attending a newborn to cause that child to be subject to newborn screening tests for conditions for which there is a medical benefit to the early detection and treatment of the disorder.
Relating to the regulation of pharmacists and the practice of pharmacy, including the administration of a medication and the ordering and administration of an immunization or vaccination by a pharmacist.